Cargando…
Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859856/ https://www.ncbi.nlm.nih.gov/pubmed/35198574 http://dx.doi.org/10.3389/fmed.2022.817578 |
_version_ | 1784654547194478592 |
---|---|
author | Kurajoh, Masafumi Mori, Katsuhito Miyabe, Mizuki Matsufuji, Shota Kizu, Akane Tsujimoto, Yoshihiro Emoto, Masanori |
author_facet | Kurajoh, Masafumi Mori, Katsuhito Miyabe, Mizuki Matsufuji, Shota Kizu, Akane Tsujimoto, Yoshihiro Emoto, Masanori |
author_sort | Kurajoh, Masafumi |
collection | PubMed |
description | BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in which increased ROS and ATP shortage are known to be involved. METHODS: This retrospective cross-sectional study included 296 HD patient (203 males, 93 females). Muscle mass, physical performance, and muscle strength were assessed using dual-energy X-ray absorptiometry, five-time chair stand testing, and handgrip strength, respectively. The Asian Working Group for Sarcopenia 2019 criteria were used to define low muscle mass, low physical performance, and low muscle strength, as well as sarcopenia and severe sarcopenia. RESULTS: Sarcopenia and severe sarcopenia prevalence rates were 42.2 and 20.9%, respectively. XOR inhibitor users (n = 119) showed a significantly (p < 0.05) lower prevalence of sarcopenia and severe sarcopenia, as well as reduced muscle mass, physical performance, and muscle strength than non-users (n = 177). Multivariate logistic regression analyses also revealed XOR inhibitor use to be significantly associated with low muscle mass [odds ratio (OR), 0.384; 95% confidence interval (CI), 0.183–0.806; p = 0.011] and low physical performance (OR, 0.286; 95% CI, 0.142–0.578; p < 0.001), while significance with low muscle strength was borderline. Furthermore, XOR inhibitor use was significantly associated with sarcopenia (OR, 0.462; 95% CI, 0.226–0.947; p = 0.035) and severe sarcopenia (OR, 0.236; 95% CI, 0.091–0.614; p = 0.003). CONCLUSIONS: XOR inhibitor use was significantly associated with reduced risk of sarcopenia/severe sarcopenia in HD patients, suggesting that XOR inhibitor treatment has protective effects on sarcopenia in HD patients. |
format | Online Article Text |
id | pubmed-8859856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88598562022-02-22 Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis Kurajoh, Masafumi Mori, Katsuhito Miyabe, Mizuki Matsufuji, Shota Kizu, Akane Tsujimoto, Yoshihiro Emoto, Masanori Front Med (Lausanne) Medicine BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in which increased ROS and ATP shortage are known to be involved. METHODS: This retrospective cross-sectional study included 296 HD patient (203 males, 93 females). Muscle mass, physical performance, and muscle strength were assessed using dual-energy X-ray absorptiometry, five-time chair stand testing, and handgrip strength, respectively. The Asian Working Group for Sarcopenia 2019 criteria were used to define low muscle mass, low physical performance, and low muscle strength, as well as sarcopenia and severe sarcopenia. RESULTS: Sarcopenia and severe sarcopenia prevalence rates were 42.2 and 20.9%, respectively. XOR inhibitor users (n = 119) showed a significantly (p < 0.05) lower prevalence of sarcopenia and severe sarcopenia, as well as reduced muscle mass, physical performance, and muscle strength than non-users (n = 177). Multivariate logistic regression analyses also revealed XOR inhibitor use to be significantly associated with low muscle mass [odds ratio (OR), 0.384; 95% confidence interval (CI), 0.183–0.806; p = 0.011] and low physical performance (OR, 0.286; 95% CI, 0.142–0.578; p < 0.001), while significance with low muscle strength was borderline. Furthermore, XOR inhibitor use was significantly associated with sarcopenia (OR, 0.462; 95% CI, 0.226–0.947; p = 0.035) and severe sarcopenia (OR, 0.236; 95% CI, 0.091–0.614; p = 0.003). CONCLUSIONS: XOR inhibitor use was significantly associated with reduced risk of sarcopenia/severe sarcopenia in HD patients, suggesting that XOR inhibitor treatment has protective effects on sarcopenia in HD patients. Frontiers Media S.A. 2022-02-07 /pmc/articles/PMC8859856/ /pubmed/35198574 http://dx.doi.org/10.3389/fmed.2022.817578 Text en Copyright © 2022 Kurajoh, Mori, Miyabe, Matsufuji, Kizu, Tsujimoto and Emoto. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Kurajoh, Masafumi Mori, Katsuhito Miyabe, Mizuki Matsufuji, Shota Kizu, Akane Tsujimoto, Yoshihiro Emoto, Masanori Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis |
title | Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis |
title_full | Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis |
title_fullStr | Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis |
title_full_unstemmed | Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis |
title_short | Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis |
title_sort | xanthine oxidoreductase inhibitor use associated with reduced risk of sarcopenia and severe sarcopenia in patients undergoing hemodialysis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859856/ https://www.ncbi.nlm.nih.gov/pubmed/35198574 http://dx.doi.org/10.3389/fmed.2022.817578 |
work_keys_str_mv | AT kurajohmasafumi xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis AT morikatsuhito xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis AT miyabemizuki xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis AT matsufujishota xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis AT kizuakane xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis AT tsujimotoyoshihiro xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis AT emotomasanori xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis |